# 1NC vs Rock Ridge

## OFF

### 1NC - Contention

Space Manufacturing

#### Commercial space manufacturing is booming --- that creates new treatments to solve diseases, but the AFF kills it --- private sector launch and appropriation is key

Giulianotti et. al 21 [Marc A. Giulianotti1\*, Arun Sharma2,3, Rachel A. Clemens4 , Orquidea Garcia5 , D. Lancing Taylor6, Nicole L. Wagner7 , Kelly A. Shepard8 , Anjali Gupta4, Siobhan Malany9 , Alan J. Grodzinsky10, Mary Kearns‐Jonker11, Devin B. Mair12, Deok‐Ho Kim12,13, Michael S. Roberts1, Jeanne F. Loring14, Jianying Hu15, Lara E. Warren1 , Sven Eenmaa1, Joe Bozada16, Eric Paljug16, Mark Roth17, Donald P. Taylor18, Gary Rodrigue1, Patrick Cantini19, Amelia W. Smith1, William R. Wagner19,20\* 1 Center for the Advancement of Science in Space, Melbourne, FL, USA 2 Board of Governors Regenerative Medicine Institute, Cedars‐Sinai Medical Center, Los Angeles, CA, USA 3 Smidt Heart Institute, Cedars‐Sinai Medical Center, Los Angeles, CA, USA 4 Axiom Space, Inc., Houston, TX, USA 5 Johnson & Johnson 3D Printing Innovation & Customer Solutions, Johnson & Johnson Services, Inc., Irvine, CA , USA. 6 University of Pittsburgh Drug Discovery Institute and Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA 7 LambdaVision Inc., Farmington, CT, USA 8 California Institute for Regenerative Medicine, Oakland, California, USA 9 Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL USA 10 Departments of Biological Engineering, Mechanical Engineering and Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA 11 Department of Pathology and Human Anatomy, Loma Linda University School of Medicine, Loma Linda, CA, USA 12 Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA 13 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA 14 Scripps Research Institute, San Diego, CA, USA 15 Center for Computational Health IBM Research, Yorktown Heights, NY, USA 16 Joseph M. Katz Graduate School of Business, University of Pittsburgh, Pittsburgh, PA, USA 17 Pittsburgh, PA, USA 18 The Ohio State University, Columbus, OH, USA 19 McGowan Institute for Regenerative Medicine, Pittsburgh, PA, USA 20 Departments of Surgery, Bioengineering, Chemical Engineering, University of Pittsburgh, Pittsburgh, PA, USA. “Opportunities for Biomanufacturing in Low Earth Orbit: Current Status and Future Directions.” August 2, 2021. https://www.preprints.org/manuscript/202108.0044/v1/download]

The use of LEO by governments and commercial enterprises is a complex ecosystem for providing opportunities and financing. In the last two decades, governments around the world, led by the U.S. and China, have heavily supported private space companies (2019 Report). These investments have focused on launch technologies, as high launch costs are perceived to be the greatest limiting factor to expanded space exploration and utilization (Werzt et al., 1996) and have led to recent reductions in the cost of transporting cargo to LEO by a factor of more than 20. Between 1970 and 2020, the average cost to launch a kilogram of payload into LEO on the space shuttle remained constant at about $54,500. Now, the cost per kilogram is $2,720 on a SpaceX Falcon 9 rocket (Figure 1) (Jones, H. W. et al., 2020). Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 August 2021 doi:10.20944/preprints202108.0044.v1 4 Figure 1: The cost of launching payloads to LEO has dropped considerably over the last 50 years. Note: Data is not to scale. Additionally, several private companies are now pursuing commercial space stations. Axiom Space, headquartered in Houston, is currently developing what promises to be the first‐ever privately operated space station, with the initial module scheduled to launch to the ISS in 2024. Axiom plans to dock multiple modules to the ISS that will eventually detach to become a standalone station. As the cost of transport to LEO has decreased—and is expected to decrease further—and plans for new platforms in LEO continue to advance (Dinkin S., 2019), opportunities in areas such as satellite deployment, biomedical research, in‐space manufacturing, and space tourism increase. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 August 2021 doi:10.20944/preprints202108.0044.v1 5 As the past half century has witnessed the opening of space for exploration and commercial opportunities, in this same period, we have experienced exponential growth in our understanding of biology and physiology. This knowledge has been translated and commercialized for the benefit of human health and continues to accelerate as new technologies create additional tools to explore and cure. One aspect of this biomedical revolution is in the field of regenerative medicine, built upon advances in stem cell biology, biomaterials, and bioengineering. Remarkable advancements have been made in the design of MPS, also called tissue chips or organs‐on‐chips, and organoids that can mimic complex organ systems outside of the body for drug development or potential implantation to restore function. Stem cell isolation, characterization, and manipulation is advancing, with target applications broadly spread across tissues impacted by disease, trauma, and congenital conditions. Biomaterials and bioengineering advances have created new medical devices, targeted drug delivery platforms, biosensors and new imaging modalities, and the bioprinting of tissue constructs. To take advantage of these significant advances—more frequent and more affordable access to LEO and exponential progress in biomedical technology—the question is: How do these intersect, and what new opportunities arise as both advance? How can the unique LEO environment be leveraged to further advance biomanufacturing? Compelling answers to these questions will introduce economic drivers for investment in space‐based R&D that extend beyond the initial focus on pure discovery and into the expansion of commercial development in LEO. Over the past decade, the ISS National Lab has supported important space‐based research in the areas of tissue engineering and regenerative medicine that lays the groundwork for more complex studies and future investment. This critical research addressed fundamental questions such as: How does the LEO environment affect the organ function mimicked by tissue chips, and how do these changes relate to human disease? How does microgravity affect stem cell proliferation and differentiation? And how might 3D bioprinting benefit from the absence of gravity? Continued access to LEO through the ISS National Lab provides a unique opportunity for R&D that enables the jump from this initial work to the development of a sustainable market for biomanufacturing in space. The ISS is a powerful platform with a limited lifetime and thus limited time left for utilization; therefore, now is the time to leverage this invaluable orbiting laboratory to conduct R&D that demonstrates the value of biomanufacturing in space. This work will set the stage for increased private investment and the transition to larger and more numerous platforms in LEO that can support further discovery and development in the coming decades

#### Future pandemics cause extinction

Diamandis 21 [Eleftheriosi, biochemist specializing in clinical chemistry, Prof and Head of Clinical Biochemistry in the Dept of Laboratory Medicine and Pathobiology at the University of Toronto] “The Mother of All Battles: Viruses vs Humans. Can Humans Avoid Extinction in 50-100 Years?” Preprints, April 13, 2021, <https://www.preprints.org/manuscript/202104.0397/v1> TG

The recent SARS-CoV-2 pandemic, which is causing COVID 19 disease, has taught us unexpected lessons about the dangers of human extinction through highly contagious and lethal diseases. As the COVID 19 pandemic is now being controlled by various isolation measures, therapeutics and vaccines, it became clear that our current lifestyle and societal functions may not be sustainable in the long term. We now have to start thinking and planning on how to face the next dangerous pandemic, not just overcoming the one that is upon us now. Is there any evidence that even worse pandemics could strike us in the near future and threaten the existence of the human race? The answer is unequivocally yes. It is not necessary to get infected by viruses of bats, pangolins and other exotic animals that live in remote forests in order to be in danger. Creditable scientific evidence indicates that the human gut microbiota harbor billions of viruses which are capable of affecting the function of vital human organs such as the immune system, lung, brain, liver, kidney, heart etc. It is possible that the development of pathogenic variants in the gut can lead to contagious viruses which can cause pandemics, leading to destruction of vital organs, causing death or various debilitating diseases such as blindness, respiratory, liver, heart and kidney failures. These diseases could result in the complete shutdown of our civilization and probably the extinction of human race. In this essay, I will first provide a few independent pieces of scientific facts and then combine this information to come up with some (but certainly not all) hypothetical scenarios that could cause human race misery, even extinction. I hope that these scary scenarios will trigger preventative measures that could reverse or delay the projected adverse outcomes.